The role of calcium in gastric acid secretion is still uncertain. The effect of verapamil on basal and pentagastrin-stimulated gastric acid secretion was evaluated in eight normal men. Submaximal pentagastrin tests (2 micrograms/kg/hr) were performed after pretreatment with intravenous verapamil at a concentration of 0.1 mg/kg and followed 1 hr later with a second bolus injection of 0.15 mg/kg. On a separate day, subjects received a placebo injection of saline solution at the same designated times as the verapamil. Verapamil did not alter basal or stimulated gastric acid secretion. All subjects showed ECG evidence of significant calcium-channel blocking (i.e., prolongation of PR interval). Data indicate that therapeutic doses of a calcium slow-channel antagonist do not alter gastric acid secretion in normal subjects. Results support the concept that in vivo, secretory function of the human parietal cell is not affected by alteration in cellular calcium flux.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.